Repression of BET activity sensitizes homologous recombination–proficient cancers to PARP inhibition

Strategies to enhance response to poly(adenosine diphosphate–ribose) polymerase inhibitor (PARPi) in primary and acquired homologous recombination (HR)–proficient tumors would be a major advance in cancer care. We used a drug synergy screen that combined a PARPi, olaparib, with 20 well-characterized...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Sci Transl Med
Main Authors: Yang, Lu, Zhang, Youyou, Shan, Weiwei, Hu, Zhongyi, Yuan, Jiao, Pi, Jingjiang, Wang, Yueying, Fan, Lingling, Tang, Zhaoqing, Li, Chunsheng, Hu, Xiaowen, Tanyi, Janos L., Fan, Yi, Huang, Qihong, Montone, Kathleen, Dang, Chi V., Zhang, Lin
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5705017/
https://ncbi.nlm.nih.gov/pubmed/28747513
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1126/scitranslmed.aal1645
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados